Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.

Interested parties may access the conference call on May 9 th , 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 15 th , 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell .

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
( ir@lineagecell.com )
(442) 287-8963

LifeSci Advisors
Daniel Ferry
( daniel@lifesciadvisors.com )
(617) 430-7576

Russo Partners – Media Relations
Nic Johnson or David Schull
( Nic.johnson@russopartnersllc.com )
( David.schull@russopartnersllc.com )
(212) 845-4242

News Provided by Business Wire via QuoteMedia

LCTX:US
The Conversation (0)
Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.

Lineage to Present at 2024 BIO International Convention

Lineage to Present at 2024 BIO International Convention

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company's CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tuesday June 4 th , 2024, at 2:30pm in Theater 3. Company representatives are also hosting meetings with potential partners and collaborators to discuss opportunities for strategic alliances across Lineage's novel pipeline of cell therapy transplant programs. The BIO International Convention is the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world, and is taking place June 3-6, 2024, at the San Diego Convention Center in San Diego, CA.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

  • Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins
  • Clinical Session Expanded to Include Neuralink
  • Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2 nd Annual Spinal Cord Injury Investor Symposium ("2 nd SCIIS"). The 2 nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations, and the investment community, in order to discuss perspectives on current and future treatment alternatives, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and broaden awareness of and investment of capital into SCI.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

  • Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program
  • Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
  • OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting
  • OPC1 Clinical Study Start Up Preparation Underway
  • Received CIRM Grant to Support 2 nd Annual SCI Investor Symposium
  • Appointed Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

"The quarter was highlighted by significant milestones and data updates on our lead program," stated Brian M. Culley, Lineage CEO. "A key area of attention for investors is our partnership with Roche and Genentech, and we are pleased to announce a new services agreement which reflects an additional commitment by Genentech for the benefit of the OpRegen program. We believe this agreement will enable our partners to take advantage of our cell transplant expertise to more fully investigate the promising potential of the OpRegen program and do so in a cost-effective manner. We also are planning to bring our second cell transplant program, OPC1, into the clinic this year for a condition with growing awareness of its unmet need and commercial opportunity. Lastly, we continue to build value through the advancement of our early-stage pipeline, which can help create value by capitalizing on the continued validation of our cell transplant approach."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
OpRegen®  Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

OpRegen® Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

  • BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10)
  • BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5)
  • Maintenance or increases in external limiting membrane (ELM) and retinal pigment epithelium (RPE) layers observed by optical coherence tomography (OCT) in patients with extensive bleb coverage of the GA lesion
  • Data suggests OpRegen may counteract RPE cell dysfunction and cell loss in GA by providing support to remaining retinal cells, with effects observed through at least 2 years following a single administration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit . The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute . The presentation, "OpRegen ® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial," was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.

Interested parties may access the conference call on May 9 th , 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 15 th , 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Osisko Gaspé Expansion Hole Intersects 133.7 Metres Averaging 1.04% Cu

Osisko Gaspé Expansion Hole Intersects 133.7 Metres Averaging 1.04% Cu

Osisko Metals Incorporated (the " Company " or " Osisko Metals ") ( TSX: OM,OTC:OMZNF ; OTCQX: OMZNF ; FRANKFURT: 0B51 ) is pleased to announce new drill results from the Gaspé Copper Project, located in the Gaspé Peninsula of Eastern Québec.

Osisko Metals CEO Robert Wares commented: "The growth potential of the Gaspé Copper deposit continues to be demonstrated with today's new high-grade results. Holes 30-1106 and 30-1109 reveal the presence of a thick, higher grade tabular zone lying at depth around the E Zone horizon near the eastern margin of our 2024 MRE model. This tabular zone may extend significantly to the east if it correlates to historical drilling results. Our expansion drilling is exceeding expectations, hand-in-hand with the solid infill results on our main resource area."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Silver47 Exploration - OTC Markets Request

Silver47 Exploration - OTC Markets Request

Silver47 Exploration Corp. (TSXV: AGA,OTC:AAGAF) (OTCQB: AAGAF) ("Silver47" or the "Company") confirms that, as previously announced on September 4, 2025, it has engaged Sideways Frequency LLC ("SFLLC") as an arms-length, third party firm contractually retained by the Company in accordance with routine industry practices to provide investor relations services for a 12 month term.

As part of the Company's efforts towards investor awareness, SFLLC organizes and facilitates the creation and distribution of promotional material concerning the Company and its common shares traded on the OTCQB marketplace (the "Promotional Material") on behalf of the Company. On September 10, 2025, the Company became aware that SFLLC had commenced distribution of Promotional Material which discussed the Company, its business and a general assessment of, and commentary on, the broader market for silver and silver exploration globally. The Promotional Material was available via email and online via click-through of digital media ads.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Vertex Minerals Limited  Corporate Presentation Mining Forum Americas

Vertex Minerals Limited Corporate Presentation Mining Forum Americas

Perth, Australia (ABN Newswire) - Flagship Project for Vertex Minerals Limited (ASX:VTX,OTC:VTXXF) (OTCMKTS:VTXXF) - Reward Gold Mine, Hill End Corporate Presentation to Mining Forum Americas.

- Commenced Gold processing with new Gekko Gravity Gold Plant

- 100% owned

- No hedge - No Secured debt - fully funded

- Low operating Cost

- High Grade Gold Resource and Reserve 225 ozs at 16.7g/t + more

- Inherited >AUD $50m of underground development

- 1.8M Au oz historically mined

- Reward sits below the Hawkins Hill Mine 435kozs at 309 g/t

- Up to 95% recovery by gravity processes only

- Big Gold System, ~21Miles (34km) with >3,000 old workings

*To view the presentation, please visit:
https://abnnewswire.net/lnk/484ZF4X8



About Vertex Minerals Limited:

Vertex Minerals Limited (ASX:VTX,OTC:VTXXF) is an Australian based gold exploration company developing its advanced Hargraves and Hill End gold projects located in the highly prospective Eastern Lachlan Fold Belt of Central West NSW. Other Company assets include the Pride of Elvire gold project and Taylors Rock gold/nickel/lithium project both located in the Eastern Goldfields of WA. The focus of Vertex Minerals is to advance the commercial production of gold from its NSW projects embracing an ethical and environmentally sustainable approach.



Source:
Vertex Minerals Limited

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Canada One Commences 2025 Field Work Program at Flagship, Copper Dome Project

Canada One Commences 2025 Field Work Program at Flagship, Copper Dome Project

Canada One Mining Corp. (TSXV: CONE) (OTC Pink: COMCF) (FSE: AU31) ("Canada One" or the "Company") is pleased to announce the launch of its 2025 field exploration program at its flagship Copper Dome Project ("Copper Dome", "Property" or "Project"), located 18 km south of Princeton, British Columbia.

2025 FIELD WORK PROGRAM HIGHLIGHTS

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Cygnus reports a 78% increase in M&I resource at its Chibougamau Copper-Gold Project

Cygnus reports a 78% increase in M&I resource at its Chibougamau Copper-Gold Project

HIGHLIGHTS:

  • Global Measured & Indicated Mineral Resource ("M&I") estimate of 6.4 Mt at 3.0% CuEq for 193kt CuEq and Inferred Mineral Resource of 8.5 Mt at 3.5% CuEq for 295 kt CuEq in accordance with JORC 2012 and CIM Definition Standards (CIM, 2014)
  • Total contained metal is exclusively Copper, Gold and Silver:
    • M&I: 149kt Cu, 167 koz Au & 1.6 Moz Ag (for 193 kt CuEq or 884 koz AuEq)
    • Inferred: 182 kt Cu, 454 koz Au & 2.2 Moz Ag (for 295 kt CuEq or 1.3 Moz AuEq)
  • This update includes an initial Mineral Resource Estimate ("MRE") for the new Golden Eye deposit and the other existing hub-and-spoke deposits of Corner Bay, Cedar Bay, Devlin, and Joe Mann
  • The initial high-grade Golden Eye resource contains:
    • Indicated: 91 koz @ 5.6 g/t AuEq
    • Inferred: 182 koz @ 4.6 g/t AuEq
  • The 78% tonnage increase in M&I Resources will underpin an updated Scoping Study / Preliminary Economic Assessment ("PEA"), which will also reflect the significant increase in commodity prices on the economics of the Project since the 2022 PEA completed by Doré Copper 1
  • Today's announcement demonstrates proven upside at the Chibougamau Project with two diamond drill rigs still turning and additional potential to add to the resource base
  • Chibougamau Project is a premier near-term development copper-gold opportunity with established infrastructure including a 900 ktpa processing facility, sealed highway, airport, regional rail infrastructure, and 25 kV hydro power to the processing site
  • The Project has excellent metallurgy with test work recoveries of up to 98.2% producing a high-quality clean copper concentrate of up to 29.6% 2
  • Cygnus is continuing to generate an exciting pipeline of exploration targets using its in-house AI-driven solution for the compilation of historic drill logs and maps; This work has proven highly successful and has helped deliver the initial Golden Eye MRE
  • The Company remains fully funded to drive further growth and the ongoing study work with A$23M cash at 30 June 2025
  • A new fly through video and resource presentation will be available in the coming week, given the finalisation of the MRE as announced today

Cygnus Executive Chairman David Southam said: "Within just nine months of acquiring the Chibougamau Project, we have been able to deliver a significant resource upgrade with substantial scope for further growth.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News